Characteristics of Recurrent Ventricular Fibrillation Associated With Inferolateral Early Repolarization Role of Drug Therapy by Haïssaguerre, Michel et al.
S
d
s
F
p
N
F
U
Y
S
Journal of the American College of Cardiology Vol. 53, No. 7, 2009
© 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00
PHeart Rhythm Disorders
Characteristics of Recurrent Ventricular Fibrillation
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Objectives Our purpose was to evaluate the efficacy of antiarrhythmic drugs (AADs) in recurrent ventricular fibrillation (VF)
associated with inferolateral early repolarization pattern on the electrocardiogram.
Background Although an implantable cardioverter-defibrillator is the treatment of choice, additional AADs may be necessary
to prevent frequent episodes of VF and reduce implantable cardioverter-defibrillator shock burden or as a lifesav-
ing therapy in electrical storms.
Methods From a multicenter cohort of 122 patients (90 male subjects, age 37  12 years) with idiopathic VF and early repo-
larization abnormality in the inferolateral leads, we selected all patients with more than 3 episodes of VF (multiple)
including those with electrical storms (3 VF in 24 h). The choice of AAD was decided by individual physicians.
Follow-up data were obtained for all patients using monitoring with implantable defibrillator. Successful oral AAD was
defined as elimination of all recurrences of VF with a minimal follow-up period of 12 months.
Results Multiple episodes of VF were observed in 33 (27%) patients. Electrical storms (34  47 episodes) occurred in 16
and were unresponsive to beta-blockers (11 of 11), lidocaine/mexiletine (9 of 9), and verapamil (3 of 3), while
amiodarone was partially effective (3 of 10). In contrast, isoproterenol infusion immediately suppressed electri-
cal storms in 7 of 7 patients. Over a follow-up of 69  58 months, oral AADs were poorly effective in preventing
recurrent VF: beta-blockers (2 of 16), verapamil (0 of 4), mexiletine (0 of 4), amiodarone (1 of 7), and class 1C
AADs (2 of 9). Quinidine was successful in 9 of 9 patients, decreasing recurrent VF from 33  35 episodes to nil
for 25  18 months. In addition, quinidine restored a normal electrocardiogram.
Conclusions Multiple recurrences of VF occurred in 27% of patients with early repolarization abnormality and may be life
threatening. Isoproterenol in acute cases and quinidine in chronic cases are effective AADs. (J Am Coll Cardiol
2009;53:612–9) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.10.044e
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February 17, 2009:612–9 Treatment of VF Associated With Early Repolarizationeristic electrocardiographic abnormalities affecting ven-
ricular repolarization such as long QT interval, short QT
nterval, or ST-segment elevation in the V1 to V3
recordial leads (Brugada syndrome) or their cardiac
xpression can be exclusively arrhythmic such as cat-
cholaminergic polymorphic ventricular tachycardia or
See page 620
diopathic ventricular fibrillation (VF) without identifi-
ble electrocardiogram (ECG) abnormalities during sinus
hythm despite drug provocation (6 –10). A recent mul-
icenter study has shown that early repolarization in the
nferolateral leads is associated with arrhythmic sudden
ardiac death in a subset of patients, accounting for 31%
f so-called idiopathic VF (11). In these patients, the
ncidence of recurrent VF treated by an implanted defi-
rillator was 41% during a follow-up of 5 years. However,
here are scarce data on the role of antiarrhythmic drugs
AADs) and their efficacy in preventing recurrences of
pisodes of VF or treating electrical storms. The present
ulticenter study reports the incidence and characteris-
ics of recurrent VF and the antiarrhythmic management
n a cohort of 122 patients.
ethods
tudy population. Thirty tertiary care arrhythmia centers
articipated in this study (Appendix). The population in-
luded 122 patients with the diagnosis of idiopathic VF and
arly repolarization on the ECG: 90 male and 32 female
ubjects, mean age 37  12 years at diagnosis, range 12 to
9 years. A history of unexplained syncope was noted in 39
atients before diagnosis. A family history of sudden death
under age 60 years) was found in 21 patients.
Early repolarization (11,12) was defined as the presence
f a QRS-ST junction (J point) deviated from the baseline
y 0.1 mV, either as a QRS slurring (smooth transition
rom QRS to ST-segment) or notching (positive J deflec-
ion inscribed on the S-wave) with or without upward
T-segment in the inferolateral leads. The absence of
tructural heart disease was demonstrated by normal size
nd function of the right and left ventricles by echocardi-
graphy in all patients. Cardiac catheterization was per-
ormed in 115 patients and showed normal coronary angio-
ram (with negative ergonovine provocation in 19), while
readmill exercise testing was normal in the 7 remaining
oung patients. Right ventricle angiogram or magnetic
esonance imaging was normal in 83 patients. Seven pa-
ients underwent right ventricular biopsy, which was nega-
ive. Long and short QT syndromes were excluded by
easurement of corrected QT intervals (corrected with
azett’s formula) at baseline and before arrhythmia ranging
etween 340 and 440 ms. Brugada syndrome was excluded
sing consensus criteria (10) by the absence of right bundle-
ranch block and ST-segment elevation (0.2 mV) in mrecordial leads V1 to V3 (includ-
ng high positioning on the
hest) at baseline and in 93 pa-
ients after provocation with at
east 1 class I AAD. Intravenous
jmaline (1 mg/kg body weight
t a rate of 10 mg/min), flecain-
de (2 mg/kg body weight over
0 min with a maximum of 150
g), cibenzoline (1.5 mg/kg body weight over 5 min), or
rocainamide (10 mg/kg at a rate of 100 mg/min) was used
determined by their availability in the participating centers).
linical and electrophysiological data. Clinical data, re-
ults of pharmacological testing, and invasive electrophysi-
logical testing were collected. All 12-lead ECGs showing
ocumentation of ventricular arrhythmias including initia-
ion of polymorphic ventricular tachycardia or VF on ECGs
ere analyzed to assess the morphology of ventricular beats.
Electrophysiological study was performed using 2 or 3
ultielectrode catheters introduced percutaneously through
he femoral vessels, consisting of measurement of the
is-to-ventricle interval and programmed ventricular stim-
lation. A maximum of 3 ventricular extrastimuli were
elivered from 2 ventricular sites. Patients with VF or
ustained ventricular tachyarrhythmia (lasting 30 s, caus-
ng syncope, or requiring intervention for termination) were
lassified as inducible. Patients with inducible nonsustained
entricular arrhythmias (6 beats that terminated sponta-
eously within 30 s) were classified as noninducible.
rug therapy, implantable cardioverter-defibrillator
ICD) implantation, and follow-up. All patients had
CD implantation, and subsequent follow-up was per-
ormed according to local practice. In the absence of
ymptoms or device therapy, patients were seen routinely
very 6 to 12 months for clinical review and device interro-
ation or as necessary in the event of symptoms or device
herapies. Appropriate shocks were defined as shocks deliv-
red for polymorphic ventricular tachycardia or VF.
In patients with recurrent arrhythmias, the choice of
ADs was decided by individual physicians. The effect of
AD therapy was assessed only in patients having at least 3
pisodes of VF before the onset of AAD. In addition, AAD
rials were assessed if they were prescribed at least at the
ollowing minimum daily doses: quinidine 450 mg, mexil-
tine 300 mg, flecainide 200 mg, propafenone 750 mg,
ilsicainide 450 mg, amiodarone 200 mg, and verapamil 240
g; the doses and types of beta-blockers were variable. An
ral AAD abolishing all recurrences of VF with at least 1
ear of follow-up was considered as successful.
An electrical storm was defined by 3 episodes of VF
ccurring within 24 h. The intravenous drugs infused
uring electrical storm were considered as effective if there
as no episode of VF after their administration and as
neffective if at least 1 more episode was observed.
tatistical analysis. Continuous variables were reported as
Abbreviations
and Acronyms
AAD  antiarrhythmic drug
ICD  implantable
cardioverter-defibrillator
IQR  interquartile range
VF  ventricular fibrillationean  SD or median (25th to 75th percentiles) as
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Treatment of VF Associated With Early Repolarization February 17, 2009:612–9ppropriate. A comparison between the groups was per-
ormed by the Student t test for independent samples.
ategorical variables were compared with the Fisher exact
est. All tests were 2-tailed, and a p value 0.05 was
onsidered indicative of statistical significance.
esults
ncidence of inducible or spontaneous recurrent VF.
able 1 shows the clinical and electrophysiological data in
he total cohort. VF was inducible in only 28% of patients
despite all being resuscitated from documented VF). The
ajority of these patients (90%) were studied using 3
xtrastimuli with the mean shortest coupling interval of the
rst delivered extrastimulus being 212  29 ms. The HV
nterval was 60 ms in all patients (mean 45  9 ms).
The patients were followed for a mean of 69  58
onths after the initial event of cardiac arrest. From the
ohort of 122 patients, 73 had no recurrence of VF, 16 had
to 3 recurrences, and 33 had multiple (more than 3)
ecurrences. The timing of the first recurrence of VF relative
o the initial cardiac arrest is shown in Figure 1.
Table 2 shows the characteristics of 33 patients with
ultiple VF episodes compared with the characteristics of
hose 89 patients with lesser episodes. Patients with multi-
le VF more frequently had a prior history of syncope (58%
s. 24%, p  0.001), a higher incidence of VF inducible
uring programmed ventricular stimulation (48% vs. 20%, p
0.01), and a higher amplitude of J point on the baseline
CG (0.24  0.12 mV vs. 0.20  0.08 mV, p  0.04).
An electrical storm was observed in 16 of the 33 patients
ith multiple VF (8 female subjects, 8 male subjects, age 38
haracteristics of the Population
Table 1 Characteristics of the Population
Variable
n
(Available Data)
Mean  SD
or Percentage
Age (yrs) 122 36 12.4
Sex
Women 32 26%
Men 90 74%
Familial history of sudden death
Yes 21 18%
No 98 82%
Syncope
Yes 39 33%
No 78 67%
PR 200
Yes 5 4%
No 110 96%
Amplitude of J-wave (mV) 112 0.21 0.09
QRS duration (ms) 119 91.8 10.4
QTc (ms) 117 394.7 26.0
EP study: VF induced
Yes 22 28%
No 57 72%
P  electrophysiological; QTc  corrected QT interval; VF  ventricular fibrillation.14 years). There was no significant difference in thelinical characteristics of 16 patients with electrical storm
ersus the other 17 with multiple VF.
lectrical storms: characteristics and effects of intrave-
ous drugs. Table 3 shows the characteristics of patients
ith electrical storms. A mean of 34  47 episodes (median
9 episodes, interquartile range [IQR] 3 to 84 episodes) per
atient were terminated by external or ICD shocks during
he electrical storms. The storm occurred during the initial
ospitalization in 10 patients: 4 were referred for resuscitated
F, 5 for syncope, and 1 patient for fever due to gastrointes-
inal disease (ulcerative colitis); in 2 patients referred for
yncope, the electrical storm occurred at admission in the
mergency unit. In 6 patients the electrical storm occurred after
CD implantation at a mean follow-up time of 33  39
onths (median 15 months, IQR 3 to 84 months). Twelve-
ead ECGs recorded during the arrhythmic periods showed a
onsistent increase in the amplitude of early repolarization
ompared with that seen in baseline (Fig. 2). In 2 of them,
/ST-segment abnormalities were confused with myocardial
schemia so that both patients underwent a coronary angio-
ram that demonstrated normal vessels.
The ectopy initiating VF had positive QRS morphology
n leads V1 to V2 in 8 cases indicating an origin from the left
entricle; it had a negative morphology in 5 cases and both
egative and positive patterns in 3 cases. The latter 3
atients exhibited widespread abnormal repolarization on a
ider territory (6 to 9 ECG leads), whereas the other 13
atients had a more localized abnormality (3 to 6 ECG
eads). The coupling interval of ectopic beats triggering VF
as 281  39 ms (range 240 to 360 ms).
Eight patients were placed under deep sedation and
echanical ventilation during the storm. Standard intrave-
ous AAD had a low efficacy. The electrical storm was
nresponsive to verapamil (3 of 3 patients), lidocaine or
exiletine (9 of 9 patients), and beta-blockers (11 of 11
atients), while amiodarone was effective in 3 of 10 patients.
hree patients were also placed under mechanical left
entricular assistance and one of them died (from mesen-
eric infarction 2 days after withdrawal of assistance).
Figure 1 Timing of Recurrence of Ventricular
Fibrillation After the Initial Cardiac Arrest
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February 17, 2009:612–9 Treatment of VF Associated With Early Repolarizationnother patient died as a result of incessant VF. Rapid atrial
acing at 90 beats/min was used effectively in 1 patient.
Isoproterenol was infused in 7 patients during repetitive
pisodes of VF (mean 25  12 episodes) at a rate of 1 to 5
g/min and eliminated all arrhythmias when the sinus heart
ate was increased above 120 beats/min. Any attempt to
educe isoproterenol infusion and heart rate was associated
ith recurrence of VF in 3 of the patients. Isoproterenol was
nfused for a period ranging from 6 h to 5 days. In addition,
soproterenol infusion reduced the early repolarization pat-
ern or restored a normal ECG (Figs. 3 to 5). Table 3
ummarizes the therapeutic history.
ffects of oral AAD on VF recurrences during long-term
ollow-up. The patients were followed-up over 69  58
onths after the initial event. Mexiletine and verapamil were
neffective in 4 of 4 patients each. Beta-blockers were ineffec-
ive in 14 patients and effective in 2 patients (follow-up 52 and
4 months, respectively). Class 1C AADs (including flecain-
de, propafenone, pilsicainide) were ineffective in 7 and effec-
ive in 2 patients (both with propafenone, follow-up 48 and 24
onths, respectively). Amiodarone was effective in 1 patient
Characteristics of 33 Patients With Multiple VF
Table 2 Characteristics of 33 Patients With
Variables n  3
Age (yrs) 38
Amplitude of J-wave (mm  10) 24.2
QRS duration 93.9
QTc 393.7
Men (vs. women) 21
Family history of sudden death 5
Syncope 19
EP study: VF induced 11
Values are mean  SD. Bold indicates significant differences.
Abbreviations as in Table 1.
linical and Therapeutic Data in 16 Patients With Electrical Storm
Table 3 Clinical and Therapeutic Data in 16 Patients With Elec
Sex, Age
(yrs)
VF During Storm
(n)
Origin of
Ectopy
Timing After ICD Implantatio
(Months)
M, 13 50 LV  RV 0
F, 52 200 LV 0
M, 37 18 RV 84
M, 59 52 LV 1
F, 45 50 LV  RV 0
F, 16 38 LV  RV 15
F, 37 8 LV 96
M, 24 28 RV 0
F, 26 6 RV 0
M, 34 8 LV 0
M, 29 5 LV 0
F, 48 17 LV 0
M, 38 14 LV 3
M, 50 20 RV 0
F, 59 4 LV 20
F, 50 20 RV 0
ctopy were considered as originating from the left ventricle (LV) or right ventricle (RV) when thei
AAD  antiarrhythmic drugs; Amio  amiodarone; BB  beta-blocker; Bretyl  bretylate; Cath  cat
exiletine; Procai  procainamide; Verap  verapamil; VF  ventricular fibrillation.follow-up 19 months) and ineffective in 6 patients (in 1 during
he loading phase, in 5 during chronic treatment); however,
one of the patients with successful action of amiodarone
uring electrical storm was treated with the oral medication.
he failure of AADs indicated an attempt at catheter ablation
f VF triggers in 8 patients with successful outcome in 6.
Quinidine (in 3) or hydroquinidine (in 6) was totally
uccessful in 9 of 9 patients decreasing the number of
ecurrent VF from a mean of 33  35/median of 25 (IQR
to 62) episodes to nil with a current follow-up of 25  18
onths on therapy. The daily dose of hydroquinidine was
00 mg in 6 patients resulting in blood levels ranging from
.7 to 4.2 g/ml (therapeutic range 2 to 5 g/ml). In
ddition, quinidine reduced the early repolarization pattern
r restored a normal ECG in all patients (Fig. 6). It is
otable that no other patient from the total cohort (from the
roups with none or 1 to 3 VF recurrences) was prescribed
uinidine.
Currently, of the 31 living patients, 22 patients have not
xperienced any defibrillator discharge: 8 patients are taking
o medication including 6 after successful catheter ablation
us Other 89 Patients
tiple VF Versus Other 89 Patients
n  89 p Value
36 11.9 0.34
19.5 7.8 0.04
91.1 9.0 0.29
395.1 23.8 0.82
69 77.5% 0.12
16 18.4% 0.73
20 23.8% 5.104
11 19.6% 0.01
l Storm
Ineffective AAD Effective Therapy Long-Term Therapy
Lido Procai BB Verap Isoproterenol No AAD
BB Amio *
Lido BB Amio Bretyl Sedation Quinidine
Lido BB Amio Isoproterenol/quinidine *
Amio Isoproterenol No AAD
Lido Fleca BB Amio Verap Isoproterenol/quinidine Quinidine
Lido Mexi BB Quinidine Quinidine
Lido Isoproterenol Cath ablation
Lido BB Amio Isoproterenol Cath ablation
Amio No AAD
BB Amio No AAD
Mexi BB Verap Sedation Cath ablation
BB Amio No AAD
Lido BB Amio Isoprenaline Cath Ablation
Lido Spontaneous resolution Quinidine
Lido BB Amio High rate pacing Pacing  BB
n in V1 lead was positive or negative, respectively. *Patient deceased.Vers
Mul
3
13.5
11.5
13.5
31.9
63.6%
15.6%
57.6%
47.8%trica
n
r patter
heter; Fleca  flecainide; ICD  implantable cardioverter-defibrillator; Lido  lidocaine; Mexi 
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Treatment of VF Associated With Early Repolarization February 17, 2009:612–9f VF triggers, 9 are taking quinidine, 2 are taking beta-
lockers, 2 are taking propafenone, and 1 is taking amio-
arone. Nine patients have experienced at least 1 appropri-
te defibrillator intervention during the last 12 months (2 on
o AAD, 7 on various AADs), and 4 of them are currently
eing considered for quinidine therapy. Four patients are
ollowed in a rehabilitation center because of adverse neu-
ologic sequelae of initial prolonged cardiac arrest.
iscussion
his multicenter study demonstrates the efficacy of 2
pecific drugs to abolish and prevent recurrences of VF
ssociated with early repolarization abnormality in the
nferolateral leads. The infusion of isoproterenol can suc-
essfully manage electrical storms sometimes as a lifesaving
herapy while the oral administration of quinidine is effec-
ive chronically on a long-term basis.
istinct ECG entity associated with sudden death. Dif-
erent electrical syndromes of arrhythmic sudden death have
een described including recently a syndrome involving an
arly repolarization anomaly in the inferior and left precor-
ial leads in 31% of patients resuscitated from unexplained
udden death (11). This study confirms this entity in an
nlarged multicenter patient population.
The early repolarization abnormality was both variable
Figure 2 Amplification of Early Repolarization Pattern During th
Electrocardiograms showing ventricular bigeminy and ventricular fibrillation (VF) init
morphologies. Also note the varying repolarization pattern. Baseline electrocardiognd labile as observed in other repolarization syndromes. ihat repolarization was linked to arrhythmogenicity was
upported by the dynamic changes affecting specifically
his ECG marker, which preceded and culminated with
rrhythmia and receded with their reversal; the origin of
rrhythmia initiating ectopy from the region of abnormal
epolarization also supported this link. Similar patients
ave also been previously described in case reports
elating “abnormal J-wave,” however, without establish-
ng the link with early repolarization syndrome or using
control population (13–25). The arrhythmogenicity of
his syndrome is thought to be related to heterogeneity of
ction potentials (spike and dome morphology in epicar-
ial tissue) across the ventricular wall at the end of phase
. Any perturbation in the balance of currents may
mplify the disparity in voltage gradient and precipitate
ocal re-entries and polymorphic ventricular arrhythmias,
roviding both the trigger and substrate of VF. Experi-
entally, sodium and calcium-channel blockers, activa-
ion of IK-ATP, hypercalcemia, and hypothermia in-
rease electrical gradient and are arrhythmogenic (26).
linically, the exogenous precipitating factors and under-
ying genetic abnormality are unknown; however, the
ncidence of death during rest or sleep indicates an
ugmenting role of increased vagal tone.
cute treatment of electrical storms. Electrical storm,
efined as 3 episodes of VF within a 24-h period, occurs
hythmic Period
(right panel) both originating from left ventricle with superior axis and different
the left panel shows discrete early repolarization in inferior leads.e Arr
iation
ram inn a minority of patients implanted with an ICD but may
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February 17, 2009:612–9 Treatment of VF Associated With Early Repolarizationause death or require heroic measures such as transplanta-
ion or left ventricular assistance to save the patient’s life.
ur study confirms the severity of electrical storm also in
ssociation with early repolarization abnormality and shows
hat continuous infusion of isoproterenol successfully treats
lectrical storm and consistently restores normal ECG in
Figure 3 Recurrence of VF After Discontinuation of Isoproteren
Each line shows 1 min of telemetric rhythm. This recording commenced 1 min afte
tion (VF) (asterisks), both terminated by implantable cardioverter-defibrillator disch
HR  the sinus heart rate in beats/min.
Figure 4 Graph Showing Multiple Episodes of VF and Their
Immediate Correction by Isoproterenol Infusion
Each dot indicates 1 episode of VF requiring electrical
shock for termination. Abbreviations as in Figure 3.mhis particular patient population. This efficacy has also been
eported in a preliminary study including the same condi-
ion (27) as well as in Brugada syndrome or in torsades de
ointes associated with bradycardia (28). Isoproterenol is
hought to be effective probably by increasing I Ca-L current
nd thus decreasing electrical gradient and possibly by increas-
ng heart rate and reducing inactivation of Ito (26).
ntiarrhythmic therapy to prevent recurrences of VF.
his study demonstrates that most AADs including beta-
lockers, class 1C, and verapamil are ineffective in patients
ith early repolarization abnormality. Previous studies have
hown the efficacy of quinidine to prevent clinical recur-
ences in idiopathic VF, Brugada syndrome, and HERG-
inked short QT syndrome (29–31). Belhassen et al. (2) also
howed the efficacy of quinidine in reducing inducibility of
F. The present study demonstrates that quinidine is
ffective in prevention of recurrence of VF associated with
arly repolarization abnormality. The patients had a partic-
larly high number of VF episodes and a long-term
ollow-up free of ICD interventions that strongly support
he efficacy of this drug. Such results have also been reported
n case reports (13,15,27). Quinidine inhibits several cur-
ents including an effect in blocking Ito, which is pivotal in
ndo-epicardial electrical gradient and the related arrhyth-
usion
ruption of isoproterenol and shows initiation of 2 episodes of ventricular fibrilla-
. The bottom tracing shows the second VF initiation at a greater magnification.ol Inf
r inter
argesogenic risk.
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Treatment of VF Associated With Early Repolarization February 17, 2009:612–9osological frontiers with Brugada syndrome. Early re-
olarization is reported as a differential diagnosis of Brugada
yndrome by the consensus committee (10). The former
ondition is distinct because of the following features: the
CG marker is absent in the right precordial leads, insensitive
Figure 5 Normalization of QRST
Morphology During Isoproterenol Infusion
The left top electrocardiogram shows major QRST abnormality during sinus bra-
dycardia of 48/min with initiation of ventricular fibrillation at the bottom trace.
The right top electrocardiogram shows normalization of QRST morphology dur-
ing isoproterenol infusion. bpm  beats/min.
Figure 6 Abolition of Early Repolarization Pattern Under Hydroq
The left electrocardiogram shows early repolarization in inferior leads in a patient
hydroquinidine 600 mg/day, there was no recurrence of ventricular fibrillation for 1o sodium channel blockers, and not associated with conduc-
ion defect or SCN5A mutation; additionally, VF originating
rom multiple locations in the right or left ventricle contrasts
ith Brugada syndrome defined as a right ventricular (outflow
ract) disease (10). However, our patients share some charac-
eristics with Brugada syndrome in that the ECG abnormality
ccurs at the early phase of repolarization and is associated with
otential arrhythmogenicity. In addition, the efficacy of iso-
roterenol and quinidine are also reminiscent of their efficacy
n Brugada syndrome. Though both conditions are manifesta-
ions of electrical heterogeneity during phase 1 of the action
otential, they may express specific ionic current density/
unction in different regions of the heart while sharing a
ommon element (for example acting in synergy with Ito
urrent). The nosological frontier between these conditions
nd confusion caused by phenotypic overlap (16–25) will
ertainly benefit from genetic studies as well as studies using
olecular or morphological imaging.
linical implications. The present clinical study improves
ecognition and treatment of individuals with malignant
rrhythmias. The incidence of early repolarization as a
otential cause of unexplained death may be underestimated
ecause of spontaneous fluctuation in the J-wave inscription
nd the rare opportunity to document arrhythmia initiation
hen repolarization changes are maximal; in addition, early
epolarization may be present but temporally cancelled
ithin the depolarization. The study shows that use of
soproterenol can be lifesaving in individuals with incessant
F. Though failure of most AADs indicates the need for an
mplantable defibrillator, the role of quinidine relative to an
CD strategy warrants further investigation.
tudy limitations. Drug testing was not uniform between
enters. In addition, this study did not provide information
o identify the few patients at high arrhythmia risk within
ine
d 36 episodes of nocturnal ventricular fibrillation in 2 years. Under
ths and associated normalization of QRS (right electrocardiogram).uinid
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CG patterns.
onclusions
his multicenter study shows that recurrences of VF are
requent in association with early repolarization abnormality
n the inferolateral leads. Isoproterenol (in acute cases) or the
ral administration of quinidine are effective in correcting the
CG pattern and suppressing recurrence of arrhythmias.
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